Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Summary

This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).

Timeline

Start

2016-12

Primary completion

2017-01

Completion

2017-01

Drugs

Indications